Dec 13, 2022 | Jessie Daw
As I mentioned in my previous blog, the uncertainties of living with smoldering multiple myeloma (SMM) can be whittled down to two “million dollar” questions: (a) “Will I progress to active disease?” and (b) “Should I consider treatment, and if so, how and when?” This...
Dec 13, 2022 | Jack Aiello
Today was the final day of ASH, but it was still full of information, and to be honest, I’m a bit brain-fried. For me, the day started with an excellent Education Spotlight session on “Underrepresented minorities in clinical trials…”. It was chaired by multiple...
Dec 10, 2022 | Jessie Daw
Friday, the first day of the 64th Annual American Society of Hematology (ASH) Annual Meeting, is symposia day. I attended the IMF’s Satellite Symposium, “A Conversation with the Myeloma Experts: Making Sense of the Evolving Treatment Landscape.” The experts were the...
